img

Global Nanocarrier-Based Vaccine Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Nanocarrier-Based Vaccine Market Insights, Forecast to 2034

Nanocarrier-based adjuvants and delivery vehicles such as viral vectors, virus-like particles and virosomes; non-viral vectors namely nanoemulsions, lipid nanocarriers, biodegradable and non-degradable nanoparticles, calcium phosphate nanoparticles, colloidally stable nanoparticles, proteosomes; and pattern recognition receptors covering c-type lectin receptors and toll-like receptors.
Market Analysis and InsightsGlobal Nanocarrier-Based Vaccine Market
Global Nanocarrier-Based Vaccine market is expected to reach to US$ 473 million in 2024, with a positive growth of %, compared with US$ 436 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Nanocarrier-Based Vaccine industry is evaluated to reach US$ 806.5 million in 2029. The CAGR will be 9.3% during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Nanocarrier-Based Vaccine market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Nanocarrier-Based Vaccine market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report



By Company


Emergent BioSolutions
Sanofi
GlaxoSmithKline Biologicals
Merck
Pfizer
Novartis
Moderna
Segment by Type
Adjuvants
Delivery Systems

Segment by Application


Hospital
Clinic
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Nanocarrier-Based Vaccine introduction, etc. Nanocarrier-Based Vaccine Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Nanocarrier-Based Vaccine
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Nanocarrier-Based Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Adjuvants
1.2.3 Delivery Systems
1.3 Market by Application
1.3.1 Global Nanocarrier-Based Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Nanocarrier-Based Vaccine Market Perspective (2018-2029)
2.2 Global Nanocarrier-Based Vaccine Growth Trends by Region
2.2.1 Nanocarrier-Based Vaccine Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Nanocarrier-Based Vaccine Historic Market Size by Region (2018-2024)
2.2.3 Nanocarrier-Based Vaccine Forecasted Market Size by Region (2024-2029)
2.3 Nanocarrier-Based Vaccine Market Dynamics
2.3.1 Nanocarrier-Based Vaccine Industry Trends
2.3.2 Nanocarrier-Based Vaccine Market Drivers
2.3.3 Nanocarrier-Based Vaccine Market Challenges
2.3.4 Nanocarrier-Based Vaccine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Nanocarrier-Based Vaccine by Players
3.1.1 Global Nanocarrier-Based Vaccine Revenue by Players (2018-2024)
3.1.2 Global Nanocarrier-Based Vaccine Revenue Market Share by Players (2018-2024)
3.2 Global Nanocarrier-Based Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Nanocarrier-Based Vaccine, Ranking by Revenue, 2021 VS 2022 VS 2024
3.4 Global Nanocarrier-Based Vaccine Market Concentration Ratio
3.4.1 Global Nanocarrier-Based Vaccine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nanocarrier-Based Vaccine Revenue in 2022
3.5 Global Key Players of Nanocarrier-Based Vaccine Head office and Area Served
3.6 Global Key Players of Nanocarrier-Based Vaccine, Product and Application
3.7 Global Key Players of Nanocarrier-Based Vaccine, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Nanocarrier-Based Vaccine Breakdown Data by Type
4.1 Global Nanocarrier-Based Vaccine Historic Market Size by Type (2018-2024)
4.2 Global Nanocarrier-Based Vaccine Forecasted Market Size by Type (2024-2029)
5 Nanocarrier-Based Vaccine Breakdown Data by Application
5.1 Global Nanocarrier-Based Vaccine Historic Market Size by Application (2018-2024)
5.2 Global Nanocarrier-Based Vaccine Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Nanocarrier-Based Vaccine Market Size (2018-2029)
6.2 North America Nanocarrier-Based Vaccine Market Size by Type
6.2.1 North America Nanocarrier-Based Vaccine Market Size by Type (2018-2024)
6.2.2 North America Nanocarrier-Based Vaccine Market Size by Type (2024-2029)
6.2.3 North America Nanocarrier-Based Vaccine Market Share by Type (2018-2029)
6.3 North America Nanocarrier-Based Vaccine Market Size by Application
6.3.1 North America Nanocarrier-Based Vaccine Market Size by Application (2018-2024)
6.3.2 North America Nanocarrier-Based Vaccine Market Size by Application (2024-2029)
6.3.3 North America Nanocarrier-Based Vaccine Market Share by Application (2018-2029)
6.4 North America Nanocarrier-Based Vaccine Market Size by Country
6.4.1 North America Nanocarrier-Based Vaccine Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Nanocarrier-Based Vaccine Market Size by Country (2018-2024)
6.4.3 North America Nanocarrier-Based Vaccine Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Nanocarrier-Based Vaccine Market Size (2018-2029)
7.2 Europe Nanocarrier-Based Vaccine Market Size by Type
7.2.1 Europe Nanocarrier-Based Vaccine Market Size by Type (2018-2024)
7.2.2 Europe Nanocarrier-Based Vaccine Market Size by Type (2024-2029)
7.2.3 Europe Nanocarrier-Based Vaccine Market Share by Type (2018-2029)
7.3 Europe Nanocarrier-Based Vaccine Market Size by Application
7.3.1 Europe Nanocarrier-Based Vaccine Market Size by Application (2018-2024)
7.3.2 Europe Nanocarrier-Based Vaccine Market Size by Application (2024-2029)
7.3.3 Europe Nanocarrier-Based Vaccine Market Share by Application (2018-2029)
7.4 Europe Nanocarrier-Based Vaccine Market Size by Country
7.4.1 Europe Nanocarrier-Based Vaccine Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Nanocarrier-Based Vaccine Market Size by Country (2018-2024)
7.4.3 Europe Nanocarrier-Based Vaccine Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Nanocarrier-Based Vaccine Market Size (2018-2029)
8.2 China Nanocarrier-Based Vaccine Market Size by Type
8.2.1 China Nanocarrier-Based Vaccine Market Size by Type (2018-2024)
8.2.2 China Nanocarrier-Based Vaccine Market Size by Type (2024-2029)
8.2.3 China Nanocarrier-Based Vaccine Market Share by Type (2018-2029)
8.3 China Nanocarrier-Based Vaccine Market Size by Application
8.3.1 China Nanocarrier-Based Vaccine Market Size by Application (2018-2024)
8.3.2 China Nanocarrier-Based Vaccine Market Size by Application (2024-2029)
8.3.3 China Nanocarrier-Based Vaccine Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Nanocarrier-Based Vaccine Market Size (2018-2029)
9.2 Asia Nanocarrier-Based Vaccine Market Size by Type
9.2.1 Asia Nanocarrier-Based Vaccine Market Size by Type (2018-2024)
9.2.2 Asia Nanocarrier-Based Vaccine Market Size by Type (2024-2029)
9.2.3 Asia Nanocarrier-Based Vaccine Market Share by Type (2018-2029)
9.3 Asia Nanocarrier-Based Vaccine Market Size by Application
9.3.1 Asia Nanocarrier-Based Vaccine Market Size by Application (2018-2024)
9.3.2 Asia Nanocarrier-Based Vaccine Market Size by Application (2024-2029)
9.3.3 Asia Nanocarrier-Based Vaccine Market Share by Application (2018-2029)
9.4 Asia Nanocarrier-Based Vaccine Market Size by Region
9.4.1 Asia Nanocarrier-Based Vaccine Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Nanocarrier-Based Vaccine Market Size by Region (2018-2024)
9.4.3 Asia Nanocarrier-Based Vaccine Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Type
10.2.1 Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Type (2018-2024)
10.2.2 Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Application
10.3.1 Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Application (2018-2024)
10.3.2 Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Country
10.4.1 Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Country (2018-2024)
10.4.3 Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Emergent BioSolutions
11.1.1 Emergent BioSolutions Company Details
11.1.2 Emergent BioSolutions Business Overview
11.1.3 Emergent BioSolutions Nanocarrier-Based Vaccine Introduction
11.1.4 Emergent BioSolutions Revenue in Nanocarrier-Based Vaccine Business (2018-2024)
11.1.5 Emergent BioSolutions Recent Developments
11.2 Sanofi
11.2.1 Sanofi Company Details
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Nanocarrier-Based Vaccine Introduction
11.2.4 Sanofi Revenue in Nanocarrier-Based Vaccine Business (2018-2024)
11.2.5 Sanofi Recent Developments
11.3 GlaxoSmithKline Biologicals
11.3.1 GlaxoSmithKline Biologicals Company Details
11.3.2 GlaxoSmithKline Biologicals Business Overview
11.3.3 GlaxoSmithKline Biologicals Nanocarrier-Based Vaccine Introduction
11.3.4 GlaxoSmithKline Biologicals Revenue in Nanocarrier-Based Vaccine Business (2018-2024)
11.3.5 GlaxoSmithKline Biologicals Recent Developments
11.4 Merck
11.4.1 Merck Company Details
11.4.2 Merck Business Overview
11.4.3 Merck Nanocarrier-Based Vaccine Introduction
11.4.4 Merck Revenue in Nanocarrier-Based Vaccine Business (2018-2024)
11.4.5 Merck Recent Developments
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Nanocarrier-Based Vaccine Introduction
11.5.4 Pfizer Revenue in Nanocarrier-Based Vaccine Business (2018-2024)
11.5.5 Pfizer Recent Developments
11.6 Novartis
11.6.1 Novartis Company Details
11.6.2 Novartis Business Overview
11.6.3 Novartis Nanocarrier-Based Vaccine Introduction
11.6.4 Novartis Revenue in Nanocarrier-Based Vaccine Business (2018-2024)
11.6.5 Novartis Recent Developments
11.7 Moderna
11.7.1 Moderna Company Details
11.7.2 Moderna Business Overview
11.7.3 Moderna Nanocarrier-Based Vaccine Introduction
11.7.4 Moderna Revenue in Nanocarrier-Based Vaccine Business (2018-2024)
11.7.5 Moderna Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Nanocarrier-Based Vaccine Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Adjuvants
Table 3. Key Players of Delivery Systems
Table 4. Global Nanocarrier-Based Vaccine Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 5. Global Nanocarrier-Based Vaccine Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Nanocarrier-Based Vaccine Market Size by Region (2018-2024) & (US$ Million)
Table 7. Global Nanocarrier-Based Vaccine Market Share by Region (2018-2024)
Table 8. Global Nanocarrier-Based Vaccine Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Nanocarrier-Based Vaccine Market Share by Region (2024-2029)
Table 10. Nanocarrier-Based Vaccine Market Trends
Table 11. Nanocarrier-Based Vaccine Market Drivers
Table 12. Nanocarrier-Based Vaccine Market Challenges
Table 13. Nanocarrier-Based Vaccine Market Restraints
Table 14. Global Nanocarrier-Based Vaccine Revenue by Players (2018-2024) & (US$ Million)
Table 15. Global Nanocarrier-Based Vaccine Revenue Share by Players (2018-2024)
Table 16. Global Top Nanocarrier-Based Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nanocarrier-Based Vaccine as of 2022)
Table 17. Global Nanocarrier-Based Vaccine Industry Ranking 2021 VS 2022 VS 2024
Table 18. Global 5 Largest Players Market Share by Nanocarrier-Based Vaccine Revenue (CR5 and HHI) & (2018-2024)
Table 19. Global Key Players of Nanocarrier-Based Vaccine, Headquarters and Area Served
Table 20. Global Key Players of Nanocarrier-Based Vaccine, Product and Application
Table 21. Global Key Players of Nanocarrier-Based Vaccine, Product and Application
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Nanocarrier-Based Vaccine Market Size by Type (2018-2024) & (US$ Million)
Table 24. Global Nanocarrier-Based Vaccine Revenue Market Share by Type (2018-2024)
Table 25. Global Nanocarrier-Based Vaccine Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Nanocarrier-Based Vaccine Revenue Market Share by Type (2024-2029)
Table 27. Global Nanocarrier-Based Vaccine Market Size by Application (2018-2024) & (US$ Million)
Table 28. Global Nanocarrier-Based Vaccine Revenue Share by Application (2018-2024)
Table 29. Global Nanocarrier-Based Vaccine Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global Nanocarrier-Based Vaccine Revenue Share by Application (2024-2029)
Table 31. North America Nanocarrier-Based Vaccine Market Size by Type (2018-2024) & (US$ Million)
Table 32. North America Nanocarrier-Based Vaccine Market Size by Type (2024-2029) & (US$ Million)
Table 33. North America Nanocarrier-Based Vaccine Market Size by Application (2018-2024) & (US$ Million)
Table 34. North America Nanocarrier-Based Vaccine Market Size by Application (2024-2029) & (US$ Million)
Table 35. North America Nanocarrier-Based Vaccine Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 36. North America Nanocarrier-Based Vaccine Market Size by Country (2018-2024) & (US$ Million)
Table 37. North America Nanocarrier-Based Vaccine Market Size by Country (2024-2029) & (US$ Million)
Table 38. Europe Nanocarrier-Based Vaccine Market Size by Type (2018-2024) & (US$ Million)
Table 39. Europe Nanocarrier-Based Vaccine Market Size by Type (2024-2029) & (US$ Million)
Table 40. Europe Nanocarrier-Based Vaccine Market Size by Application (2018-2024) & (US$ Million)
Table 41. Europe Nanocarrier-Based Vaccine Market Size by Application (2024-2029) & (US$ Million)
Table 42. Europe Nanocarrier-Based Vaccine Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. Europe Nanocarrier-Based Vaccine Market Size by Country (2018-2024) & (US$ Million)
Table 44. Europe Nanocarrier-Based Vaccine Market Size by Country (2024-2029) & (US$ Million)
Table 45. China Nanocarrier-Based Vaccine Market Size by Type (2018-2024) & (US$ Million)
Table 46. China Nanocarrier-Based Vaccine Market Size by Type (2024-2029) & (US$ Million)
Table 47. China Nanocarrier-Based Vaccine Market Size by Application (2018-2024) & (US$ Million)
Table 48. China Nanocarrier-Based Vaccine Market Size by Application (2024-2029) & (US$ Million)
Table 49. Asia Nanocarrier-Based Vaccine Market Size by Type (2018-2024) & (US$ Million)
Table 50. Asia Nanocarrier-Based Vaccine Market Size by Type (2024-2029) & (US$ Million)
Table 51. Asia Nanocarrier-Based Vaccine Market Size by Application (2018-2024) & (US$ Million)
Table 52. Asia Nanocarrier-Based Vaccine Market Size by Application (2024-2029) & (US$ Million)
Table 53. Asia Nanocarrier-Based Vaccine Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 54. Asia Nanocarrier-Based Vaccine Market Size by Region (2018-2024) & (US$ Million)
Table 55. Asia Nanocarrier-Based Vaccine Market Size by Region (2024-2029) & (US$ Million)
Table 56. Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Type (2018-2024) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Type (2024-2029) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Application (2018-2024) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Application (2024-2029) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 61. Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Country (2018-2024) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Country (2024-2029) & (US$ Million)
Table 63. Emergent BioSolutions Company Details
Table 64. Emergent BioSolutions Business Overview
Table 65. Emergent BioSolutions Nanocarrier-Based Vaccine Product
Table 66. Emergent BioSolutions Revenue in Nanocarrier-Based Vaccine Business (2018-2024) & (US$ Million)
Table 67. Emergent BioSolutions Recent Developments
Table 68. Sanofi Company Details
Table 69. Sanofi Business Overview
Table 70. Sanofi Nanocarrier-Based Vaccine Product
Table 71. Sanofi Revenue in Nanocarrier-Based Vaccine Business (2018-2024) & (US$ Million)
Table 72. Sanofi Recent Developments
Table 73. GlaxoSmithKline Biologicals Company Details
Table 74. GlaxoSmithKline Biologicals Business Overview
Table 75. GlaxoSmithKline Biologicals Nanocarrier-Based Vaccine Product
Table 76. GlaxoSmithKline Biologicals Revenue in Nanocarrier-Based Vaccine Business (2018-2024) & (US$ Million)
Table 77. GlaxoSmithKline Biologicals Recent Developments
Table 78. Merck Company Details
Table 79. Merck Business Overview
Table 80. Merck Nanocarrier-Based Vaccine Product
Table 81. Merck Revenue in Nanocarrier-Based Vaccine Business (2018-2024) & (US$ Million)
Table 82. Merck Recent Developments
Table 83. Pfizer Company Details
Table 84. Pfizer Business Overview
Table 85. Pfizer Nanocarrier-Based Vaccine Product
Table 86. Pfizer Revenue in Nanocarrier-Based Vaccine Business (2018-2024) & (US$ Million)
Table 87. Pfizer Recent Developments
Table 88. Novartis Company Details
Table 89. Novartis Business Overview
Table 90. Novartis Nanocarrier-Based Vaccine Product
Table 91. Novartis Revenue in Nanocarrier-Based Vaccine Business (2018-2024) & (US$ Million)
Table 92. Novartis Recent Developments
Table 93. Moderna Company Details
Table 94. Moderna Business Overview
Table 95. Moderna Nanocarrier-Based Vaccine Product
Table 96. Moderna Revenue in Nanocarrier-Based Vaccine Business (2018-2024) & (US$ Million)
Table 97. Moderna Recent Developments
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Nanocarrier-Based Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Nanocarrier-Based Vaccine Market Share by Type: 2022 VS 2029
Figure 3. Adjuvants Features
Figure 4. Delivery Systems Features
Figure 5. Global Nanocarrier-Based Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 6. Global Nanocarrier-Based Vaccine Market Share by Application: 2022 VS 2029
Figure 7. Hospital Case Studies
Figure 8. Clinic Case Studies
Figure 9. Other Case Studies
Figure 10. Nanocarrier-Based Vaccine Report Years Considered
Figure 11. Global Nanocarrier-Based Vaccine Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 12. Global Nanocarrier-Based Vaccine Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Nanocarrier-Based Vaccine Market Share by Region: 2022 VS 2029
Figure 14. Global Nanocarrier-Based Vaccine Market Share by Players in 2022
Figure 15. Global Top Nanocarrier-Based Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nanocarrier-Based Vaccine as of 2022)
Figure 16. The Top 10 and 5 Players Market Share by Nanocarrier-Based Vaccine Revenue in 2022
Figure 17. North America Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 18. North America Nanocarrier-Based Vaccine Market Share by Type (2018-2029)
Figure 19. North America Nanocarrier-Based Vaccine Market Share by Application (2018-2029)
Figure 20. North America Nanocarrier-Based Vaccine Market Share by Country (2018-2029)
Figure 21. United States Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Canada Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Europe Nanocarrier-Based Vaccine Market Size YoY (2018-2029) & (US$ Million)
Figure 24. Europe Nanocarrier-Based Vaccine Market Share by Type (2018-2029)
Figure 25. Europe Nanocarrier-Based Vaccine Market Share by Application (2018-2029)
Figure 26. Europe Nanocarrier-Based Vaccine Market Share by Country (2018-2029)
Figure 27. Germany Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. France Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. U.K. Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Italy Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Russia Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Nordic Countries Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. China Nanocarrier-Based Vaccine Market Size YoY (2018-2029) & (US$ Million)
Figure 34. China Nanocarrier-Based Vaccine Market Share by Type (2018-2029)
Figure 35. China Nanocarrier-Based Vaccine Market Share by Application (2018-2029)
Figure 36. Asia Nanocarrier-Based Vaccine Market Size YoY (2018-2029) & (US$ Million)
Figure 37. Asia Nanocarrier-Based Vaccine Market Share by Type (2018-2029)
Figure 38. Asia Nanocarrier-Based Vaccine Market Share by Application (2018-2029)
Figure 39. Asia Nanocarrier-Based Vaccine Market Share by Region (2018-2029)
Figure 40. Japan Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. South Korea Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. China Taiwan Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Southeast Asia Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. India Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Australia Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size YoY (2018-2029) & (US$ Million)
Figure 47. Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Share by Type (2018-2029)
Figure 48. Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Share by Application (2018-2029)
Figure 49. Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Share by Country (2018-2029)
Figure 50. Brazil Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 51. Mexico Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 52. Turkey Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 53. Saudi Arabia Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Israel Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. GCC Countries Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. Emergent BioSolutions Revenue Growth Rate in Nanocarrier-Based Vaccine Business (2018-2024)
Figure 57. Sanofi Revenue Growth Rate in Nanocarrier-Based Vaccine Business (2018-2024)
Figure 58. GlaxoSmithKline Biologicals Revenue Growth Rate in Nanocarrier-Based Vaccine Business (2018-2024)
Figure 59. Merck Revenue Growth Rate in Nanocarrier-Based Vaccine Business (2018-2024)
Figure 60. Pfizer Revenue Growth Rate in Nanocarrier-Based Vaccine Business (2018-2024)
Figure 61. Novartis Revenue Growth Rate in Nanocarrier-Based Vaccine Business (2018-2024)
Figure 62. Moderna Revenue Growth Rate in Nanocarrier-Based Vaccine Business (2018-2024)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries